Teva Pharmaceutical Industries Ltd
TASE:TEVA
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3 533
6 982
|
| Price Target |
|
We'll email you a reminder when the closing price reaches ILS.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd
Gross Profit
Teva Pharmaceutical Industries Ltd
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Teva Pharmaceutical Industries Ltd
TASE:TEVA
|
Gross Profit
$8.3B
|
CAGR 3-Years
2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-3%
|
|
|
Sol Gel Technologies Ltd
NASDAQ:SLGL
|
Gross Profit
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
I
|
InterCure Ltd
TASE:INCR
|
Gross Profit
₪108.3m
|
CAGR 3-Years
53%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
32%
|
|
|
Mediwound Ltd
NASDAQ:MDWD
|
Gross Profit
$2.7m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
|
S
|
Seach Medical Group Ltd
TASE:SEMG
|
Gross Profit
₪42.5m
|
CAGR 3-Years
32%
|
CAGR 5-Years
44%
|
CAGR 10-Years
N/A
|
|
|
R
|
Rekah Pharmaceutical Industry Ltd
TASE:REKA
|
Gross Profit
₪75.4m
|
CAGR 3-Years
4%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-2%
|
|
Teva Pharmaceutical Industries Ltd
Glance View
Teva Pharmaceutical Industries Ltd., a pivotal player in the global pharmaceutical landscape, has carved out its niche as one of the world's largest generic drug manufacturers. Founded in 1901 and headquartered in Petah Tikva, Israel, Teva has grown through a series of strategic acquisitions and robust research and development initiatives, thereby establishing a diverse portfolio that includes both generic medications and innovative biopharmaceuticals. The company is particularly known for its vast offerings in pain management, central nervous system disorders, and respiratory therapies, positioning itself as a vital resource for accessible healthcare solutions around the globe. With operations in over 60 countries and a commitment to providing affordable medications, Teva plays a significant role in expanding the reach of essential treatments, driving patient adherence and improving health outcomes. However, Teva's journey has not been without challenges. The company has faced various headwinds, including increasing competition in the generic market, pricing pressures, and legal battles related to opioid litigations. Investors should note that Teva is currently focused on restructuring efforts to enhance operational efficiency and strengthen its balance sheet. While navigating these complexities, the company also invests in innovative drug development, aiming to diversify its pipeline and capitalize on high-growth therapeutic areas. Teva's forward-looking strategies offer an intriguing investment proposition, as they combine the potential for stability through generics with the growth opportunities found in its specialty pharmaceuticals, making it a compelling option for those looking to invest in the evolving pharmaceutical sector.
See Also
What is Teva Pharmaceutical Industries Ltd's Gross Profit?
Gross Profit
8.3B
USD
Based on the financial report for Jun 30, 2024, Teva Pharmaceutical Industries Ltd's Gross Profit amounts to 8.3B USD.
What is Teva Pharmaceutical Industries Ltd's Gross Profit growth rate?
Gross Profit CAGR 10Y
-3%
Over the last year, the Gross Profit growth was 12%. The average annual Gross Profit growth rates for Teva Pharmaceutical Industries Ltd have been 2% over the past three years , 2% over the past five years , and -3% over the past ten years .
You don't have any saved screeners yet
